When we analyzed the data carefully, we found that other low-risk genetic alterations, e.g. NPM1 mutation with wild-type FLT3-ITD, usually had low TIM-3 expression level, and some intermediate-risk AML patients also had high TIM-3 expression level. Here, FLT3 is linked to acute myeloid leukemia.